New drug cocktail shows promise for rare HIV-Linked cancer
NCT ID NCT02659930
First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This early-phase trial tests whether combining two anti-cancer drugs, pomalidomide and liposomal doxorubicin, can safely treat advanced or hard-to-treat Kaposi sarcoma. The study includes 62 adults, some with HIV. Participants receive the drugs in 4-week cycles and are monitored for side effects and tumor response. The goal is to find a safe and effective dose combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.